Author

N. Van de Velde

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

The Potential Public Health Benefit of mRNA-1010 for Influenza Among Older Adults >=65 Years in the United States

Background/ObjectivesOlder adults are at high risk of influenza-related severe disease and complications. HD-IIV, currently recommended for adults [≥]65 years, is egg-based and may be subject to egg-adapted mutations. An mRNA-based vaccine for influenza, mRNA-1010, has been approved by the Food and Drug Administration....

K. Fust, E. Beck, M. Kohli et al. · medRxiv · 0 citations

Open access Aug 2026

Estimating the Relative Vaccine Efficacy of mRNA-1010 to High-Dose Influenza Vaccine in Adults ≥65 Years Using a Correlate of Protection Framework

Background/objective: Older adults experience a disproportionate burden of severe influenza. In the P303 trial (NCT058279789), mRNA-1010 showed greater immunogenicity versus high-dose inactivated influenza vaccine (HD-IIV4) in adults ≥65 years of age. Here, we used a correlate-of-protection framework to estimate the re...

V. Nguyen, Ethan Settembre, John Youhanna et al. · Vaccines · 0 citations

Open access Aug 2026

Indirect comparison of mRNA-1010 versus enhanced influenza vaccines in adults aged 65 years and older during the 2024-2025 US influenza season.

MRNA-1010, a new mRNA-based influenza vaccine, was shown to be comparable to currently licensed EVs among older adults ≥65 years against medically attended influenza outcomes, and provides an additional comparable option to existing EVs to help further reduce severe influenza disease burden.

K. Joshi, A. Situ, D. Mehta et al. · Journal of Medical Economics · 1 citation